Abstract. Integrin signaling may modulate several different functions involved in cell migration, invasion, proliferation and motility, and is a potential candidate biomarker for oral cancer. In the present study, a total of four integrin genes were evaluated as potential biomarkers of oral squamous cell carcinoma (OSCC). Gene expression was determined using the reverse transcription-quantitative polymerase chain reaction in 55 OSCC and 55 matched normal oral tissues. The performance of individual and combined biomarkers was analyzed by receiver operating characteristic (ROC) analysis based on the relative mRNA expression (OSCC vs. matched oral tissue from the tumor-free margin), which was calculated using the ΔΔCq value (ΔCq of OSCC-ΔCq of oral tissue from the tumor-free margin of the same patient). In the individual ROC analysis, the areas under the ROC curve (AUCs) of relative mRNA expression (ΔΔCq) of integrin subunit α3 (ITGA3), integrin subunit α5 (ITGA5), integrin subunit β1 (ITGB1) and integrin subunit β6 (ITGB6) in all tumor locations were 0.724, 0.698, 0.640 and 0.657, respectively. For locations 2 (tongue/mouth part) and 3 (edentulous ridge), their individual AUC values were 0.840, 0.765, 0.725 and 0.763, respectively. In the cumulative ROC analysis, ITGA3, ITGA5 and ITGB1 genes exhibited the highest combined AUC values (0.809 and 0.871 for all locations and locations 2 and 3 combined, respectively) compared with other biomarker combinations. In conclusion, the results of the present study identified that higher mRNA expressions of ITGA3, ITGA5, ITGB1 and ITGB6 genes are suitable for OSCC diagnosis biomarkers. Cumulative ROC analysis indicated an improved overall performance compared with the best individual integrin biomarker of OSCC.
Introduction
Oral squamous cell carcinoma (OSCC) represents the sixth most common type of cancer worldwide (1) . Several biomarkers for OSCC have been demonstrated previously (2-7) and may be useful for the diagnosis and prognosis of oral cancer. As carcinogenesis is a multistep process, a number of genes involved in the diagnosis of oral cancer have not been identified.
Integrins are a family of transmembrane-type receptor proteins on the cell surface, composed of heterodimeric complexes of 1α chain and 1β chain. The 18α and 8β subunits comprise ~24 different integrin receptors, each of which is capable of binding to a specific type of cell surface and extracellular matrix (ECM) protein ligand (8) . They function in specific signal transduction and adhesive interactions between cells, and between cells and the ECM. Integrin signaling may Evaluation of the mRNA expression levels of integrins α3, α5, β1 and β6 as tumor biomarkers of oral squamous cell carcinoma modulate several different functions involved in cell motility, invasion, proliferation and migration (9, 10) . Furthermore, integrin signaling may also affect vascular neogenesis (11) . Therefore, integrins serve an important role in tumor growth and metastasis (12) (13) (14) . Integrin subunit α3 (ITGA3), which combines with integrin subunit β1 (ITGB1) to form integrin α3β1, is the receptor for ECM molecules including fibronectin, laminin and collagen (8, 12) . Integrin α3β1 has been demonstrated to function in cell proliferation, migration and motility, and in the maintenance of basement membrane integrity (15) (16) (17) (18) . Several previous studies identified that integrin α3β1 was overexpressed and associated with tumor invasion and metastasis in the majority of types of cancer, including lung (19) and breast (20) cancer cell lines. Integrin subunit α5 (ITGA5) often combines with ITGB1 to form integrin α5β1, and serves as a receptor for fibronectin and fibrinogen to participate in cell differentiation, cell development and wound healing (8, 12) . It was identified that the emergence of integrin α5β1 expression is associated with tumor progression in lung cancer (21) . ITGA5 may also promote tumor metastasis in oral cancer cell lines (22) . Integrin subunit β6 (ITGB6) is the β subunit of integrin αvβ6, which is a receptor for fibronectin and cytotactin, and regulates cell invasion, inhibits apoptosis, modulates matrix metalloproteases and activates transforming growth factor β1 (8, 23) . Overexpression of integrin αvβ6 promotes epithelial-to-mesenchymal transition and is associated with cell invasion in oral cancer cell lines (24, 25) . However, the majority of these previous studies were focused on OSCC cell line models or non-quantitative immunohistochemical analyses of OSCC tissues. These studies did not use receiver-operating characteristic (ROC) curve analyses, which provide sensitivity and specificity data for the evaluation of OSCC biomarker performances.
In the present study, the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis was used to determine the mRNA expression levels of ITGA3, ITGA5, ITGB1 and ITGB6 genes in OSCC tissues from different tumor locations for ROC curve analyses, in order to identify suitable biomarker genes for the diagnosis of early-stage OSCC. The mRNA expression of ITGA3, ITGA5, ITGB1, and ITGB6 genes were identified as potential OSCC biomarkers. Furthermore, cumulative ROC analysis of integrin OSCC biomarkers had an improved diagnostic performance compared with individual ROC analysis.
Materials and methods
Tissue samples. The present study was approved by the Institutional Review Board at Kaohsiung Medical University (Kaohsiung, Taiwan) (approval no. KMUH-IRB-930104), and all patients provided written informed consent. A total of 55 oral tumors and 55 matched normal oral control tissues (at least 2.5 cm between tumor and control tissues) were collected (December 2004 to December 2009) from the Department of Oral and Maxillofacial Surgery, Kaohsiung Medical University Hospital. The age range of this patient cohort is 30-90 years and the median age is 50 years. All samples were blindly examined by at least three pathologists of the Department of pathology, Kaohsiung Medical University Hospital. All control tissues underwent pathological diagnosis for confirmation as non-tumor. All oral tumors underwent pathological diagnosis for OSCC and tumor stage classification used the Tumor-Node-Metastasis (TNM) system (26) . The characteristics of the patients with OSCC are summarized in Table I , this basic patient information has been described previously (6) .
RT-qPCR.
Tissues were sliced and placed into 1.5 ml microcentrifuge tubes containing TRIzol ® reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA) for homogenization using a disposable tissue grinder pestle. Subsequently, the homogenized mixtures were used for total RNA extraction according to the manufacturer's protocol. RT was performed using an OmniScript RT kit (Qiagen GmbH, Hilden, Germany). qPCR was performed using an iQ SYBR Green Supermix (Bio-Rad Laboratories, Inc., Hercules, CA, USA) in an iCycler MyiQ real-time machine (Bio-Rad Laboratories, Inc.). The relative mRNA expressions of ITGA3, ITGA5, ITGB1 and ITGB6 genes in OSCCs and controls were examined. The forward and reverse primer sequences, and the lengths of PCR products, for these genes are provided in (27) . The threshold cycle (Cq) value of each integrin gene was subtracted from the Cq value for the GAPDH reference housekeeping gene. Melting curve analyses by qPCR analysis and gel electrophoresis by 1.5% agarose containing 0.5 µg/ml ethidium bromide for visualization under a UV box were used to validate the PCR products as described previously (28) .
Statistical analysis. Data were analyzed by the Mann-Whitney test and Kruskal-Wallis test using SPSS version 17.0 software (SPSS, Inc., Chicago, IL, USA). ROC curve analyses were commonly used to evaluate the performance of cancer diagnosis (29) (30) (31) (32) (33) (34) . Accordingly, ROC curves were used to examine the performance of ITGA3, ITGA5, ITGB1 and ITGB6 genes as predictive biomarkers for detecting OSCC. Cut-off values for individual ROC curves were calculated using the 60 -ΔCq value, where 60 represents the total PCR cycle number, and no signal was assigned to the Cq value for 60, as described previously (5, 6) . For individual ROC analysis, the area under the ROC curve (AUC) of each biomarker was used to evaluate its performance as an OSCC biomarker.
To consider the combined effect of each biomarker, the cumulative ROC analysis of biomarkers was performed for OSCC prediction. At first, the critical (cut-off) point of the ROC curve for each biomarker was identified using JMP version 10 statistic software (SAS Institute Inc., Cary, NC, USA). Subsequently, biomarkers that were more relevant to the OSCC (those with values greater than the cut-off point in AUC of individual ROC results) were assigned a score of 1 (for example, values greater than the cut-off point from the AUC analysis of the individual ROC results), and the remaining biomarkers were assigned a score of 0. The combined scores for different combinations of biomarkers were calculated using the formula function in JMP 10. Finally, the combined scores were used for cumulative ROC analysis of biomarkers for comparison.
Results

Comparison of clinicopathological features and relative mRNA expressions of ITGA3, ITGA5, ITGB1 and ITGB6 genes in patients with OSCC.
To evaluate the performance of the OSCC biomarkers, mRNA expression levels of ITGA3, ITGA5, ITGB1 and ITGB6 genes of OSCC samples were evaluated by comparing tumor samples with control samples (oral tissues from the tumor-free margin). In different locations (Table III) , the differences in ITGA3 and ITGB6 gene expression levels were significant (P=0.05 and 0.005, respectively by Kruskal-Wallis test); however, the differences in the ITGA5 and ITGB1 gene expression levels were non-significant. In contrast, the differences in mRNA expression levels of ITGA3, ITGA5, ITGB1 and ITGB6 genes were non-significant at different stages (I-IV) (P= 0.19, 0.58, 0.92, and 0.53, respectively by Kruskal-Wallis test) and for the T parameter (1-4) of the TNM staging system (a measure of tumor diameter/dimension) among patients with OSCC (P= 0.36, 0.97, 0.75, and 0.83, respectively by Kruskal-Wallis test). Table IV, (Fig. 1A) . At a specificity of 50.91% for all locations (Table V, As the differences in ITGA3 and ITGB6 gene expression by location were significant (Table III) , whether the different locations of OSCC may affect the mRNA expression levels of these four integrin genes was additionally investigated. In the example of locations 2 and 3 combined (locations 2/3), i.e., the tongue/mouth floor and edentulous ridge (Fig. 1B) This basic patient information has been described previously (6) . TNM, Tumor-Node-Metastasis; Others, lower lip/vestibule/soft palate; OSCC, oral squamous cell carcinoma; +, yes; -, no.
Comparison of patient habits and relative mRNA expression of ITGA3, ITGA5, ITGB1, and ITGB6 genes in patients with OSCC. As indicated in
locations 2/3 combined (Fig. 1B) for these four integrin genes were increased compared with those of all locations together (Fig. 1A) . Analysis of different sensitivities suggested that ITGA3 and ITGA5 genes exhibited an improved specificity performance compared with that of ITGB1 and ITGB6 genes for locations 2/3 ( 
Discussion
The overexpression of ITGA3, ITGA5, I TGB1 and ITGB6 genes has been demonstrated in several types of cancer (19) (20) (21) (22) (23) (24) (25) ; however, the suitability for ITGA3, ITGA5, ITGB1 and ITGB6 genes as OSCC biomarkers has rarely been considered.
The results of the present study identified that ITGA3 and ITGB1 mRNA were overexpressed in patients with OSCC.
Similarly, it was demonstrated previously that ITGA3 and ITGB1 proteins were overexpressed in prostate tumor tissues, and knockdown of ITGA3 and ITGB1 genes by small interfering RNAs inhibited cell migration and invasion in prostate cancer cells (35) . In the present study, ITGA5 mRNA was overexpressed in patients with OSCC. Similarly, ITGA5 and ITGB1 genes have been suggested to be potential biomarkers for non-small cell lung cancer (36) . In addition, the ITGB6 gene may be a prognostic biomarker for invasive breast Table IV . Comparison of patient habits and relative mRNA expression levels of ITGA3, ITGA5, ITGB1 and ITGB6 genes in oral squamous cell carcinoma samples with control samples (oral tissue from the tumor-free margin). cancer (37) . However, to the best of our knowledge, these integrin biomarkers have rarely been investigated in OSCC.
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In the present study, individual ROC analyses for all locations identified ITGA3 and ITGA5 genes as good biomarkers for OSCC (AUC= 0.724 and 0.698, respectively), but ITGB1 and ITGB6 genes performed poorly for OSCC prediction (AUC <0.66). Compared with all locations, improved AUC values for ITGA3, ITGA5, ITGB1 and ITGB6 genes were observed in combined locations 2 and 3 (the tongue/mouth part and edentulous ridge).
Previous studies have indicated that a combination of several variants generally provides an improved diagnostic power for ROC analysis compared with ROC analysis of individual markers (38) (39) (40) (41) . A combination of several biomarkers may therefore improve the diagnostic results for tumors, as has been demonstrated in thyroid cancer (42) . Similarly, with the exception of the combination of ITGB1 and ITGB6 (AUC= 0.686), the present study identified that the majority of the biomarker combinations, including a combination of two (ITGA3/ITGA5 mRNA has been repeatedly demonstrated to be a reliable material for the diagnosis of oral cancer (5, 6, 43, 44) . For example, tissue and salivary mRNA biomarkers are suggested to be associated with clinicopathological parameters for the diagnosis of OSCC (44) . In clinical practice, the data from the present study of combined integrin biomarkers may be applied for non-invasive diagnosis of OSCC using saliva material for OSCC in the future.
An advantage of the proposed methods of the present study is a potential improvement of the AUC performance by using accumulative ROC analysis for the mRNA expression of a combination of integrin biomarkers. A disadvantage of this method is that it is based on tissue samples for mRNA evaluation, which are susceptible to degradation by RNase contamination (45) . Additionally, expression at mRNA transcriptome levels will not always be consistent with those at protein levels in cases of posttranslational modification (46) . Additionally, the present study did not provide information concerning depth of invasion, which is important for clinicians. Additional protein evaluation for ITGA3, ITGA5, ITGB1 and ITGB6 using immunohistochemistry is warranted. In addition, 5/55 the patients included in the present study were female, which may provide a gender bias for these biomarker predictions for oral cancer. Therefore, it is suggested that a larger cohort of female and male patients should be studied in the future to provide an unbiased prediction using these integrins. In the present study, the association between integrin expression and prognosis, was not analyzed which would have been beneficial to improve the reliability of the proposed integrin mRNA biomarker combination for oral cancer prediction.
Alcohol drinking, betel quid chewing and cigarette smoking are well-known risk factors for oral cancer (47) , although non-smoking and betel quid non-chewing individuals may also suffer from oral cancer (48) . It is possible that these habits may affect the initiation and progression of oral carcinogenesis, but do not directly affect the overexpression of certain genes in patients with OSCC. For example, no significant differences in the expression levels of the ITGA3, ITGA5, ITGB1 and ITGB6 biomarkers were observed between the OSCC and control tissues for each of these variables.
In conclusion, individual ROC analysis provides a sensitive and specific evaluation of biomarkers for OSCC diagnosis and prognosis. The results of the present study demonstrated that ITGA3 and ITGA5 genes were improved prognostic OSCC biomarkers for all locations compared with ITGB1 and ITGB6 genes, based on individual ROC analysis. However, ITGA3, ITGA5, ITGB1 and ITGB6 genes became more promising OSCC biomarkers when considering specific tumor locations (2 and 3; tongue/mouth part and edentulous ridge, respectively). Additionally, the cumulative ROC analyses indicated that the combination of ITGA3, ITGA5 and ITGB1 genes exhibited the highest AUC values for locations 2/3 and all locations. Therefore, ITGA3, ITGA5, ITGB1 and ITGB6 genes are suggested to be good OSCC biomarkers, and cumulative ROC analysis is hypothesized to provide an improved strategy for cancer biomarker identification.
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